AstraZeneca to invest 120 million in UK to expand the production of Zoladex which could treat prostate and breast cancer with good worldwide sales.  The investment secures 300 existing Zoladex jobs at the site and will create over 200 temporary jobs during the construction and commissioning phase between now and early 2017.

Zoladex is a widely prescribed luteinizing hormone-releasing hormone analog (LHRHa) therapy administered by a subcutaneous injection. LHRHas works by reducing testosterone or oestradiol production. Zoladex is one of the world’s leading therapies for prostate cancer, with proven survival data, offering similar overall survival benefits and improvements in quality of life compared to surgical castration (orchidectomy).

First launched in 1987, Zoladex is available in more than 100 countries. It has indications in prostate and breast cancer and is an important oncology product for AstraZeneca, with annual sales in excess of approximately $1 billion.